Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219753 | 0.92 | POLB (0.42) | POLBGAALMNASMN1; SMN2HTT | |
| SCHEMBL17545209 | 0.89 | TRIM24 (0.46) | POLBGAALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL17545075 | 0.87 | ACLY (0.51) | POLBGAALMNASMN1; SMN2HTT | |
| SCHEMBL21549607 | 0.85 | ALDH1A1 (0.46) | POLBGAALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL17545360 | 0.84 | ALDH1A1 (0.48) | POLBGAALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL21275832 | 0.83 | LMNA (0.51) | GAALMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL15882573 | 0.81 | NOTUM (0.51) | LMNATRIM24KMT2APKMNOTUM | |
| SCHEMBL29707960 | 0.81 | NOTUM (0.51) | LMNATRIM24KMT2APKMNOTUM | |
| SCHEMBL18391782 | 0.80 | LMNA (0.47) | POLBGAALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19219754 | 0.79 | XIAP (0.44) | POLBGAALMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180312-B1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | UNIV LOYOLA CHICAGO (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | POLB 1517/4885GAA 682/4885LMNA 3262/4885 |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | POLB 1517/4885GAA 682/4885LMNA 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.